Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 849 results for "gilead sciences"

Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014
Securities Technology Monitor

Gilead Q3 Earnings Preview: Sovaldi Drives Another Brilliant Q...

Gilead Sciences is expected to report upbeat earnings for the third quarter on Oct. 28, as it witnesses another high-growth quarter on the back of Sovaldi's sales Page 1 of 2 Click Ticker to See live coverage Gilead Sciences, Inc. ( ... Bidness Etc, 8 hours ago

37 images for gilead sciences

American Banking News, 1 week ago
RIA Novosti, 1 week ago
Stockhouse Bulletin Boards, 1 week ago
BusinessWeek, 1 week ago
Chicago Daily Herald, 1 week ago
Jutia Group, 1 week ago
Value Walk, 2 weeks ago
I Stock Analyst, 1 day ago
Securities Technology Monitor, 1 day ago
Seeking Alpha, 2 days ago

AHF to Gilead: Do Your Patriotic Duty and Lower Hep. C Drug Prices for Veterans

AIDS organization calls out Gilead Sciences for offering its Hepatitis C drugs Sovaldi and Harvoni to India and other countries for $900, yet charging the U.S. Department of Veteran Affairs nearly $50,000 per veteran. With rates of Hepatitis C ...
 BusinessWeek4 hours ago AHF TO GILEAD : Do Your Patriotic Duty and Lower Hep. C Drug Prices for Veterans  4 Traders4 hours ago
The Guardian Express

FDA Release: Gilead Sciences, Inc.'s Harvoni?? (ledipasvir/sofosbuvir) Approved For The Treatment Of Chronic Hepatitis C, Genotype 1 Infection In Adults; To Distribute

FLINT, Mich. , Oct. 22, 2014 /PRNewswire/ -- U.S. Food and Drug Administration (FDA) announced October 10, 2014 that Gilead Sciences Harvoni ® (ledipasvir/sofosbuvir) product was approved for the treatment of chronic hepatitis C, genotype 1 ...
 BioSpace3 hours ago DIPLOMAT PHARMACY : Harvoni┬« (ledipasvir/sofosbuvir) approved for the treatment of chronic hepatitis C, genotype 1 infection in adults; Diplomat to distribute  4 Traders1 day ago Diplomat Pharmacy Inc's Harvoni (ledipasvir/sofosbuvir) approved for the treatment of chronic hepatitis C, genotype 1 infection in adults  Reuters UK11 hours ago Harvoni┬« (ledipasvir/sofosbuvir) approved for the treatment of chronic hepatitis C, genotype 1 infection in adults; Diplomat to distribute  Individual.com1 day ago

Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $104.98

Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $102.21 today and has reached the first level of resistance at $103.59. Investors may be interested in a cross of the next upside pivot targets of $104.98
 Individual.com2 days ago Gilead Sciences (GILD) Approaches New Upside Target of $104.98  Individual.com2 days ago Shares of Gilead Sciences Receive a Boost, Up 4.8%  Individual.com6 days ago Gilead Sciences (GILD) Crosses Pivot Point Resistance at $100.16  Individual.com6 days ago
Motley Fool

What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock

Since Olysio is commonly prescribed with Sovaldi and J&J reported its third quarter earnings last week, let's take a closer look and see what J&J's results may say about Gilead's third quarter performance. Hand in hand Olysio has proven a ...
 Motley Fool3 days ago Is Johnson & Johnson's Worst Nightmare Becoming Reality?  Motley Fool1 day ago 3 Drugs Critical to Johnson & Johnson's Future  Motley Fool2 days ago

Gilead Sciences: Pricing, Politics And Profits

Summary The political flack over Gilead's HVC pricing continues. Pricing concerns are overblown. As a best in class market leader, Gilead will dominate and shares will eclipse $150 within 12 months. The other day I was rifling through the ...
 Seeking Alpha2 days ago
Seeking Alpha

Gilead Sciences (GILD): Clear The Dockets And Settle With Merck Already

Summary The patent disputes of Gilead (GILD) with Merck (MRK) and AbbVie (ABBV) are not frivolous. Merck/Idenix have valid patents with claims on the structure of the Sovaldi active metabolite. AbbVie has 2 patents that claim Harvoni. The stakes ...
 Seeking Alpha2 days ago Gilead Sciences: Clear The Dockets And Settle With Merck Already  Seeking Alpha2 days ago

Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.45% Rise

(Comtex SmarTrend(R)) Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $100.82 to a high of $103.59. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $102.32 on volume of ...
 Individual.com3 days ago Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.45%  TradingCharts.com3 days ago
Seeking Alpha

Gilead: Stage Set For Rally

Summary The dip in the shares of Gilead Sciences last week presented a good opportunity to add additional shares in this cheap biotech juggernaut. The company has several positive catalysts on the horizon that should power the next stage of the ...
 Seeking Alpha3 days ago

Lowest PEG Ratio in the Biotechnology Industry Detected in Shares of Gilead Sciences (GILD, ANIK, ACOR, CELG, ALXN)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the lowest price to earnings to growth (PEG) ratios. PEG is valuable in assessing the tradeoff between the price of a stock and expected growth. Generally, the ...
 Individual.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less